Abivax is growing revenue at 35% year-over-year with analyst consensus implying 52% upside to the price target, but cash burn running at -2,327% of revenue and a quality profile below the minimum quality threshold make this a high-risk, speculative situation where the growth must eventually translate into cash economics.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
With free cash flow at -2,327% of revenue, a negative operating margin of -1.7%, and debt-to-equity of 4.1, the company exhibits the defining characteristics of a value trap: headline revenue growth alongside severe capital consumption that may not be sustainable. Warnings | This pillar is invalidated if the cash burn rate improves to less than 500% of revenue and operating margins turn positive for 2 consecutive quarters. | →Stable |
| CounterA recent analyst coverage event produced a positive sentiment signal, and the 35% revenue growth rate may represent early-stage scale-up dynamics where negative cash flow is expected before a key catalyst converts the economics. | ||
Revenue has grown 35% year-over-year, a rate that, if sustained, would provide the top-line momentum needed to eventually close the cash burn gap and improve unit economics as the business scales. Growth breakdown | Revenue growth stays above 20% year-over-year for the next two reported periods, demonstrating the growth trajectory is not decelerating. | →Stable |
| CounterCash is burning at -2,327% of revenue and the Rule of 40 score is deeply negative at -2,291, suggesting that growth is being purchased at an unsustainable cost; capital may run short before the growth compounds to profitability. | ||
Analysts have set a consensus price target implying 52% upside to $129.71 from the current price of $98.26, and a recent analyst event contributed a positive sentiment signal of +0.60; if the growth narrative holds, this coverage could attract a broader investor base. Sentiment breakdown | Analyst consensus price target holds above $120.00 over the next 6 months; additional analyst initiations appear. | →Stable |
| CounterThe average EPS surprise across the last four quarters is -52%, indicating analysts have consistently overestimated performance; large price targets in deeply cash-negative names often carry limited predictive value and can compress rapidly on negative news. | ||
With free cash flow at -2,327% of revenue, a negative operating margin of -1.7%, and debt-to-equity of 4.1, the company exhibits the defining characteristics of a value trap: headline revenue growth alongside severe capital consumption that may not be sustainable.
→Stable- Expectation
- This pillar is invalidated if the cash burn rate improves to less than 500% of revenue and operating margins turn positive for 2 consecutive quarters.
CounterA recent analyst coverage event produced a positive sentiment signal, and the 35% revenue growth rate may represent early-stage scale-up dynamics where negative cash flow is expected before a key catalyst converts the economics.
Revenue has grown 35% year-over-year, a rate that, if sustained, would provide the top-line momentum needed to eventually close the cash burn gap and improve unit economics as the business scales.
→Stable- Expectation
- Revenue growth stays above 20% year-over-year for the next two reported periods, demonstrating the growth trajectory is not decelerating.
CounterCash is burning at -2,327% of revenue and the Rule of 40 score is deeply negative at -2,291, suggesting that growth is being purchased at an unsustainable cost; capital may run short before the growth compounds to profitability.
Analysts have set a consensus price target implying 52% upside to $129.71 from the current price of $98.26, and a recent analyst event contributed a positive sentiment signal of +0.60; if the growth narrative holds, this coverage could attract a broader investor base.
→Stable- Expectation
- Analyst consensus price target holds above $120.00 over the next 6 months; additional analyst initiations appear.
CounterThe average EPS surprise across the last four quarters is -52%, indicating analysts have consistently overestimated performance; large price targets in deeply cash-negative names often carry limited predictive value and can compress rapidly on negative news.
▸ Show 1 more pillar▾ Show fewer
Although the stock trades below its 200-day moving average, that average is still rising at +7.4% per month and on-balance volume is accumulating — suggesting the recent price weakness may be a pullback within an intact uptrend rather than a structural breakdown.
→Stable- Expectation
- Price recovers above the 200-day moving average within 2 months while the moving average slope remains positive.
CounterMomentum has failed its required minimum threshold, MACD is negative, and implied volatility of 146% indicates the market is pricing extreme uncertainty; the uptrend read may prove premature if capital needs force a dilutive capital raise.
Abivax SA (ABVX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $92.52: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 2.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend.
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in... Read more
Sell if holding. Engine safety override at $92.52: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 2.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: RSI 52 mid-range, Bollinger mid-band. Score 5.9/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 89d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
Recent developments
updated 2026-06-25Recent Developments — Abivax SA
Latest news
- NEWS BTIG Reiterates Buy on Abivax, Maintains $150 Price Target — benzinga Jun 16, 2026 positive
- NEWS 10 Health Care Stocks Whale Activity In Today's Session — benzinga Jun 5, 2026 neutral
- NEWS What's Going On With Abivax Stock On Thursday? — benzinga Jun 4, 2026 neutral
- NEWS 12 Health Care Stocks Moving In Wednesday's Intraday Session — benzinga Jun 3, 2026 neutral
- NEWS Navitas Semiconductor, Abivax, MiniMed And Other Big Stocks Moving Higher On Wednesday — benzinga Jun 3, 2026 positive
Generated 2026-06-25T01:58:03Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·2 ceiling hits
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $92.52: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 2.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: RSI 52 mid-range, Bollinger mid-band. Prior stop was $86.03. Score 5.9/10, moderate confidence.
Take-profit target: $131.13 (+41.7% upside). Prior stop was $86.03. Stop-loss: $86.03.
Quality below floor (3.5 < 4.0); Value-trap signals (2/5): Margin compression (op margin -1.7%), High leverage (D/E 4.1).
Abivax SA trades at a P/E of N/A (forward -29.9). TrendMatrix value score: 9.0/10. Verdict: Sell.
14 analysts cover ABVX with a consensus score of 4.3/5. Average price target: $151.
What does Abivax SA do?ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural...
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.